Treatment of motor dysfunction in Parkinson's disease: an overview.
Identifieur interne : 000F04 ( PubMed/Curation ); précédent : 000F03; suivant : 000F05Treatment of motor dysfunction in Parkinson's disease: an overview.
Auteurs : Stéphane Thobois [France] ; Florence Delamarre-Damier ; Pascal DerkinderenSource :
- Clinical neurology and neurosurgery [ 0303-8467 ] ; 2005.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (therapeutic use), Deep Brain Stimulation, Dyskinesias (etiology), Dyskinesias (therapy), Globus Pallidus (surgery), Humans, Nerve Growth Factors (therapeutic use), Neurons (transplantation), Neuroprotective Agents (therapeutic use), Parkinson Disease (complications), Thalamus (surgery).
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Nerve Growth Factors, Neuroprotective Agents.
- complications : Parkinson Disease.
- etiology : Dyskinesias.
- surgery : Globus Pallidus, Thalamus.
- therapy : Dyskinesias.
- transplantation : Neurons.
- Animals, Deep Brain Stimulation, Humans.
Abstract
Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.
DOI: 10.1016/j.clineuro.2005.02.002
PubMed: 15885384
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000F44
Links to Exploration step
pubmed:15885384Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of motor dysfunction in Parkinson's disease: an overview.</title><author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stéphane" last="Thobois">Stéphane Thobois</name><affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Delamarre Damier, Florence" sort="Delamarre Damier, Florence" uniqKey="Delamarre Damier F" first="Florence" last="Delamarre-Damier">Florence Delamarre-Damier</name></author><author><name sortKey="Derkinderen, Pascal" sort="Derkinderen, Pascal" uniqKey="Derkinderen P" first="Pascal" last="Derkinderen">Pascal Derkinderen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15885384</idno><idno type="pmid">15885384</idno><idno type="doi">10.1016/j.clineuro.2005.02.002</idno><idno type="wicri:Area/PubMed/Corpus">000F44</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F44</idno><idno type="wicri:Area/PubMed/Curation">000F04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F04</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of motor dysfunction in Parkinson's disease: an overview.</title><author><name sortKey="Thobois, Stephane" sort="Thobois, Stephane" uniqKey="Thobois S" first="Stéphane" last="Thobois">Stéphane Thobois</name><affiliation wicri:level="1"><nlm:affiliation>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Lyon</wicri:regionArea></affiliation></author><author><name sortKey="Delamarre Damier, Florence" sort="Delamarre Damier, Florence" uniqKey="Delamarre Damier F" first="Florence" last="Delamarre-Damier">Florence Delamarre-Damier</name></author><author><name sortKey="Derkinderen, Pascal" sort="Derkinderen, Pascal" uniqKey="Derkinderen P" first="Pascal" last="Derkinderen">Pascal Derkinderen</name></author></analytic><series><title level="j">Clinical neurology and neurosurgery</title><idno type="ISSN">0303-8467</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Deep Brain Stimulation</term><term>Dyskinesias (etiology)</term><term>Dyskinesias (therapy)</term><term>Globus Pallidus (surgery)</term><term>Humans</term><term>Nerve Growth Factors (therapeutic use)</term><term>Neurons (transplantation)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (complications)</term><term>Thalamus (surgery)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Nerve Growth Factors</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term><term>Thalamus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Neurons</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Deep Brain Stimulation</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15885384</PMID><DateCreated><Year>2005</Year><Month>05</Month><Day>11</Day></DateCreated><DateCompleted><Year>2005</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2009</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-8467</ISSN><JournalIssue CitedMedium="Print"><Volume>107</Volume><Issue>4</Issue><PubDate><Year>2005</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Clinical neurology and neurosurgery</Title><ISOAbbreviation>Clin Neurol Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Treatment of motor dysfunction in Parkinson's disease: an overview.</ArticleTitle><Pagination><MedlinePgn>269-81</MedlinePgn></Pagination><Abstract><AbstractText>Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the use of this drug is complicated by several adverse effects, in particular motor fluctuations and dyskinesias. Drugs providing more continuous dopaminergic stimulation and surgical approaches, such as deep-brain stimulation, have an important ameliorative effect on these problems. Despite these advances, the progression of the disease remains unaffected and strategies that slow or stop the neurodegenerative process are currently not available. Nevertheless, several compounds or surgical procedures are candidates for being neuroprotective and some of them are under evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thobois</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service de Neurologie, Hôpital Neurologique Pierre Wertheimer, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delamarre-Damier</LastName><ForeName>Florence</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Derkinderen</LastName><ForeName>Pascal</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Neurol Neurosurg</MedlineTA><NlmUniqueID>7502039</NlmUniqueID><ISSNLinking>0303-8467</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018696">Neuroprotective Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020820" MajorTopicYN="N">Dyskinesias</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005917" MajorTopicYN="N">Globus Pallidus</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName><QualifierName UI="Q000637" MajorTopicYN="N">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018696" MajorTopicYN="N">Neuroprotective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013788" MajorTopicYN="N">Thalamus</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>171</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>5</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15885384</ArticleId><ArticleId IdType="pii">S0303-8467(05)00031-4</ArticleId><ArticleId IdType="doi">10.1016/j.clineuro.2005.02.002</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F04 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000F04 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:15885384
|texte= Treatment of motor dysfunction in Parkinson's disease: an overview.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15885384" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |